Clinical Trials Logo

Clinical Trial Summary

The purpose of the study is to determine safety, efficacy, tolerability and Pharmacokinetics of ARGX-113 in Patients with Primary Immune Thrombocytopenia.


Clinical Trial Description

This is a randomized, double-blind, placebo-controlled Phase II study in which approximately 36 patients will be randomized in a 1:1:1 ratio to receive either ARGX-113 Dose A, or ARGX-113 Dose B body weight or placebo in 4 infusions administered 1-week apart in addition to Standard-of-Care (SoC) treatment. Patients aged 18 to 85 years (inclusive) with confirmed primary immune thrombocytopenia (ITP) who have a platelet count ˂ 30 × 109/L and who are receiving oral corticosteroids and/or permitted oral immunosuppressants and/or Thrombopoietin receptor (TPO-R) agonist as SoC which must be maintained on a stable dose and frequency for at least 4 weeks prior to Screening. The study will include a 2-week Screening, a 3-week Treatment period, and an 21-week follow-up (FU) period. The study is followed by an open label period where patients will be given the option to be treated with ARGX-113 Dose A in cycles of 4 weekly infusions with a minimum of 4 weeks apart. Patients may receive rescue therapy during the study at the discretion the investigator when deemed medically necessary. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03102593
Study type Interventional
Source argenx
Contact
Status Completed
Phase Phase 2
Start date March 13, 2017
Completion date April 9, 2019

See also
  Status Clinical Trial Phase
Completed NCT05621330 - Efficacy and Safety of QL0911 in Adult Patients With Chronic Primary Immune Thrombocytopenia Phase 3
Active, not recruiting NCT04278924 - A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia Phase 2
Recruiting NCT06148389 - The Safety and Tolerability of STSA-1301 Subcutaneous Injection in Healthy Subjects Phase 1
Active, not recruiting NCT04812925 - A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia Phase 3
Recruiting NCT06107582 - Longitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP)
Recruiting NCT05371743 - Plasma microRNA Levels and Some Cytokines Expression in Patients With ITP Primary Immune Thrombocytopenic Purpura (ITP)
Not yet recruiting NCT05311930 - Efficacy and Safety of TPO Receptor Agonists in the Treatment of Elderly ITP Patients Phase 4
Not yet recruiting NCT05333861 - An Observational, Multicenter Study to Evaluate the Safety and Effectiveness of Hetrombopag in Patients With ITP or AA
Not yet recruiting NCT06291415 - The Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HMPL-523 in Adult Subjects With Immune Thrombocytopenia (ITP) Phase 1
Completed NCT06071520 - Andalusian Experience in the Use of Fostamatinib in Patients With ITP. FOSTASUR Study
Recruiting NCT04949009 - Avatrombopag in the Treatment of Primary Immune Thrombocytopenia(ITP)
Terminated NCT04224688 - A Study to Assess the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) Phase 3
Active, not recruiting NCT04225156 - A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). Phase 3
Completed NCT05551624 - Evaluation of the Effect in Platelet Count of Atorvastatin and N-acetyl Cysteine Early Phase 1
Recruiting NCT05422365 - Intravenous Immunoglobulin (IVIG, Bioven) Efficacy and Safety in Chronic Primary Immune Thrombocytopenia (ITP) in Adults Phase 3
Terminated NCT03275740 - A First in HumanTrial to Evaluate The Safety, Tolerability, And Pharmacokinetics Of PF-06755347 Phase 1
Terminated NCT04596995 - A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) Phase 3
Terminated NCT04200456 - A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP) Phase 3
Recruiting NCT05653219 - A Study of Efficacy and Safety of Ianalumab Versus Placebo in Addition to Eltrombopag in Primary Immune Thrombocytopenia Patients Who Failed Steroids Phase 3
Completed NCT01727232 - Efficacy and Safety of Rituximab Given at Fixed Dose (1000 mg on Days 1 and 15) Compared to the Standard Regimen in Adult's Immune Thrombocytopenia N/A